Work plan for the Committee for Veterinary Medicinal Products (CVMP) Immunologicals Working Party (IWP) 2026
Work plan for the Committee for Veterinary Medicinal Products (CVMP) Scientific Advice Working Party (SAWP-V) for 2026
Stability testing for applications for variations to marketing authorisation - Scientific guideline
Guideline on stability testing for applications for variations to a marketing authorisation - Revision 3
Human medicines European public assessment report (EPAR): Teriflunomide Viatris (previously Teriflunomide Mylan), teriflunomide, Date of authorisation: 09/11/2022, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Darunavir Viatris (previously Darunavir Mylan), darunavir, Date of authorisation: 03/01/2017, Revision: 17, Status: Authorised
Human medicines European public assessment report (EPAR): Tobi Podhaler, tobramycin, Date of authorisation: 20/07/2011, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): Afstyla, lonoctocog alfa, Date of authorisation: 04/01/2017, Revision: 12, Status: Authorised
Highlights - 20th EMA Industry Platform meeting on the operation of EU pharmacovigilance legislation meeting
New variations guidelines: webinar for marketing authorisation holders (human), Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 13 January 2026, 13:00 (CET) to 13 January 2026, 15:00 (CET)